Experimental prostate cancer therapy given to one patient in last-resort treatment
NCT ID NCT06836648
First seen Feb 28, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This trial provides a single patient with advanced prostate cancer access to an experimental treatment called X-PACT, which combines a light-sensitive drug (methoxsalen) with X-rays to kill tumor cells and possibly trigger an immune response. The patient has no other standard treatment options left. The goal is to control the cancer locally and potentially throughout the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
AVAILABLEWashington D.C., District of Columbia, 20016, United States
Conditions
Explore the condition pages connected to this study.